370例女性继发性不孕症患者支原体感染分析

目的 分析继发性不孕症女性支原体感染状况,为临床诊治提供参考.方法 采用回顾性分析方法,选取解放军广州总医院生殖中心门诊就诊的继发性不孕症女性患者370例作为不孕组,将同期半年内自然受孕女性300例作为对照组.收集2组患者妇科检查数据及解脲支原体和人型支原体培养结果,对所有数据进行统计学分析.结果 不孕组患者解脲支原体和人型支原体的阳性率分别为57.8%和7.6%,高于对照组(20.0%和1.7%)(P均<0.05);不孕组患者单项感染206例(55.7%),混合感染18例(4.9%);不孕组支原体阳性患者其输卵管堵塞、子宫内膜病变、盆腔粘连及流产史的发生率显著高于阴性者(P均<0.05).结论 继发性不孕症患者支原体感染率高,且支原体感染者盆腔输卵管病变发生率增高,提示支原体感染可能是继发性不孕症发病的重要因素之一,育龄妇女应加强支原体的筛查和治疗.

Analysis of mycoplasma infection in 370 female patients with secondary infertility

Objective To analyze the role of mycoplasma infection in female patients with secondary infertility, and provide reference for clinical diagnosis and treatment.MethodsBy using retrospective analysis, 370 female patients with secondary infertility were selected from Reproductive Center of General Hospital of Guangzhou Military Command of PLA, as infertility group, while 300 natural pregnant women served as the control group. Gynecological examination data, results ofUreaplasma urealyticum (Uu) and Mycoplasma hominis (Mh) infection were collected and analyzed statistically.ResultsThe incidence of tubal obstruction, pelvic adhesion, endometrial lesions and abortion were significantly higher in the infertility group than those in the control group (P<0.05). The positive rates of Uu and Mh were 57.8% and 7.6% in the infertility group, which were significantly higher than those in the control group (20.0%, 1.7%)(P<0.05). There were 206 cases (55.7%) with single infection and 18 cases (4.9%) with mixed infection in the infertility group. The incidence of fallopian tubal blockage, endometrial lesions, pelvic adhesion and abortion history in infertile patients with mycoplasma infection were significantly higher than those in uninfected patients (P<0.05).ConclusionsSecondary infertility patients have a high prevalence of mycoplasma, and mycoplasma infected patients are associated with an increased incidence of pelvic fallopian tube lesions, suggesting that mycoplasma infection is a possible key factors leading to secondary infertility. Women of childbearing age should strengthen mycoplasma screening and treatment.